Document Detail


Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.
MedLine Citation:
PMID:  17009081     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-beta-1b (subcutaneous administration). She had taken no drug except for the IFN-beta-1b. Because nephrotic syndrome may be induced by IFN therapy, the IFN was stopped. Percutaneous renal biopsy revealed that she had minimal change nephrotic syndrome. As nephrotic-range proteinuria, hypoalbuminemia, and general edema were worsening even 2 weeks after cessation of the drug, oral corticosteroid therapy (prednisolone 40 mg/day) was started. The nephrotic syndrome was treated successfully with prednisolone. The dosage of prednisolone was tapered, without a relapse, and then the corticosteroid therapy was stopped. IFN-beta-1b therapy was then resumed, and the patient is in remission for both nephrotic syndrome and MS. Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-beta-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.
Authors:
Ryuichiro Kumasaka; Norio Nakamura; Kenichi Shirato; Takeshi Fujita; Reiichi Murakami; Michiko Shimada; Masayuki Nakamura; Hiroshi Osawa; Hideaki Yamabe; Ken Okumura
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  10     ISSN:  1342-1751     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-29     Completed Date:  2006-12-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  222-5     Citation Subset:  IM    
Affiliation:
The Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. rkuma-cc@umin.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / adverse effects*,  therapeutic use
Adult
Biopsy
Female
Glucocorticoids / therapeutic use
Humans
Interferon-beta / adverse effects*,  therapeutic use
Kidney / pathology
Multiple Sclerosis / drug therapy*
Nephrosis, Lipoid / chemically induced*,  drug therapy,  pathology
Prednisolone / therapeutic use
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Glucocorticoids; 145155-23-3/interferon beta-1b; 50-24-8/Prednisolone; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tubulointerstitial nephritis and uveitis syndrome associated with hyperthyroidism.
Next Document:  An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: ...